S&P 500   4,071.70
DOW   34,429.88
QQQ   291.43
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
"The Bull Market Is Officially OVER"  (Ad)pixel
Intel is a Sleeping Giant Ready to Awaken
As Musk is learning, content moderation is a messy job
5 Hypergrowth Stocks to Own in 2023 (Ad)pixel
Is Salesforce Stock a Bargain Down Here?
Reformers take 6 of 14 UAW board seats, could win majority
5 Hypergrowth Stocks to Own in 2023 (Ad)pixel
'Wakanda Forever' is No. 1 for 4th straight weekend
World Cup fans find booze at hotels, Qatar's 1 liquor store
S&P 500   4,071.70
DOW   34,429.88
QQQ   291.43
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
"The Bull Market Is Officially OVER"  (Ad)pixel
Intel is a Sleeping Giant Ready to Awaken
As Musk is learning, content moderation is a messy job
5 Hypergrowth Stocks to Own in 2023 (Ad)pixel
Is Salesforce Stock a Bargain Down Here?
Reformers take 6 of 14 UAW board seats, could win majority
5 Hypergrowth Stocks to Own in 2023 (Ad)pixel
'Wakanda Forever' is No. 1 for 4th straight weekend
World Cup fans find booze at hotels, Qatar's 1 liquor store
S&P 500   4,071.70
DOW   34,429.88
QQQ   291.43
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
"The Bull Market Is Officially OVER"  (Ad)pixel
Intel is a Sleeping Giant Ready to Awaken
As Musk is learning, content moderation is a messy job
5 Hypergrowth Stocks to Own in 2023 (Ad)pixel
Is Salesforce Stock a Bargain Down Here?
Reformers take 6 of 14 UAW board seats, could win majority
5 Hypergrowth Stocks to Own in 2023 (Ad)pixel
'Wakanda Forever' is No. 1 for 4th straight weekend
World Cup fans find booze at hotels, Qatar's 1 liquor store
S&P 500   4,071.70
DOW   34,429.88
QQQ   291.43
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
"The Bull Market Is Officially OVER"  (Ad)pixel
Intel is a Sleeping Giant Ready to Awaken
As Musk is learning, content moderation is a messy job
5 Hypergrowth Stocks to Own in 2023 (Ad)pixel
Is Salesforce Stock a Bargain Down Here?
Reformers take 6 of 14 UAW board seats, could win majority
5 Hypergrowth Stocks to Own in 2023 (Ad)pixel
'Wakanda Forever' is No. 1 for 4th straight weekend
World Cup fans find booze at hotels, Qatar's 1 liquor store
NASDAQ:BLRX

BioLineRx - BLRX Stock Forecast, Price & News

$0.72
+0.03 (+3.67%)
(As of 12/2/2022 03:50 PM ET)
Add
Compare
Today's Range
$0.69
$0.72
50-Day Range
$0.60
$0.95
52-Week Range
$0.57
$3.02
Volume
2,500 shs
Average Volume
240,124 shs
Market Capitalization
$44.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

BioLineRx MarketRank™ Forecast

Analyst Rating
N/A
0.00 Rating Score
Upside/​Downside
738.6% Upside
$6.00 Price Target
Short Interest
Healthy
0.42% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.51) to ($0.53) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.30 out of 5 stars

Medical Sector

993rd out of 1,033 stocks

Pharmaceutical Preparations Industry

482nd out of 502 stocks

BLRX stock logo

About BioLineRx (NASDAQ:BLRX) Stock

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

Receive BLRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioLineRx and its competitors with MarketBeat's FREE daily newsletter.

BLRX Stock News Headlines

BLRX: Cast Off the Bowlines: Aphexda Commercialization
Form 6-K BioLineRx Ltd. For: Sep 21 - StreetInsider.com
BioLineRx Announces $15 Million Registered Direct Offering
BLRX: September NDA - Benzinga
See More Headlines
Receive BLRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioLineRx and its competitors with MarketBeat's FREE daily newsletter.

BLRX Company Calendar

Last Earnings
12/08/2021
Today
12/05/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/15/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BLRX
Employees
38
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.00
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+733.3%
Consensus Rating
N/A
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

Net Income
$-27,050,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.43 per share

Miscellaneous

Free Float
60,847,000
Market Cap
$44.30 million
Optionable
Not Optionable
Beta
1.79

Key Executives

  • Mr. Philip A. Serlin CPA (Age 62)
    M.B.A., CPA, MBA, Chief Exec. Officer
    Comp: $644k
  • Ms. Mali Zeevi CPA (Age 46)
    CPA, Chief Financial Officer
    Comp: $391k
  • Dr. Ella Sorani (Age 54)
    Chief Devel. Officer
    Comp: $414k
  • Dr. Abi Vainstein-Haras M.D. (Age 47)
    Chief Medical Officer
    Comp: $391k
  • Advocate Norman Kotler (Age 70)
    Internal Enforcement Officer, Gen. Counsel and Corp. Sec.
  • Ms. Liron Shemesh-Darvish M.B.A.
    Ph.D., Sr. Director & Head of Preclinical Devel.
  • Ms. Jael Birenberg M.Sc.
    Sr. Director & Head of RA, QA and PhV
  • Ms. Tsipi Keren-Lehrer B.Sc.
    L.L.B., Head of BD & Strategic Advisor
  • Ms. Holly W. May M.B.A.
    Pres of BioLineRx USA
  • Mr. Raziel Fried
    Treasurer & Budgetary Control Director













BLRX Stock - Frequently Asked Questions

What is BioLineRx's stock price forecast for 2023?

0 Wall Street analysts have issued 1 year price objectives for BioLineRx's stock. Their BLRX share price forecasts range from $6.00 to $6.00. On average, they anticipate the company's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 738.6% from the stock's current price.
View analysts price targets for BLRX
or view top-rated stocks among Wall Street analysts.

How have BLRX shares performed in 2022?

BioLineRx's stock was trading at $2.04 at the beginning of the year. Since then, BLRX shares have decreased by 64.9% and is now trading at $0.7155.
View the best growth stocks for 2022 here
.

Are investors shorting BioLineRx?

BioLineRx saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 260,200 shares, an increase of 7.3% from the October 31st total of 242,500 shares. Based on an average trading volume of 363,300 shares, the short-interest ratio is presently 0.7 days.
View BioLineRx's Short Interest
.

When is BioLineRx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 15th 2023.
View our BLRX earnings forecast
.

How were BioLineRx's earnings last quarter?

BioLineRx Ltd. (NASDAQ:BLRX) issued its quarterly earnings results on Wednesday, December, 8th. The biotechnology company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.01.

What other stocks do shareholders of BioLineRx own?
What is BioLineRx's stock symbol?

BioLineRx trades on the NASDAQ under the ticker symbol "BLRX."

Who are BioLineRx's major shareholders?

BioLineRx's stock is owned by many different institutional and retail investors. Top institutional investors include Altium Capital Management LP (6.74%), Armistice Capital LLC (4.55%), Renaissance Technologies LLC (0.11%), Apollon Wealth Management LLC (0.08%), PVG Asset Management Corp (0.10%) and Virtu Financial LLC (0.08%).

How do I buy shares of BioLineRx?

Shares of BLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioLineRx's stock price today?

One share of BLRX stock can currently be purchased for approximately $0.72.

How much money does BioLineRx make?

BioLineRx (NASDAQ:BLRX) has a market capitalization of $44.02 million. The biotechnology company earns $-27,050,000.00 in net income (profit) each year or ($0.49) on an earnings per share basis.

How can I contact BioLineRx?

BioLineRx's mailing address is 2 HAMA-AYAN STREET, MODI-IN L3, 7177871. The official website for the company is www.biolinerx.com. The biotechnology company can be reached via phone at (728) 642-9100, via email at ir@biolinerx.com, or via fax at 972-8642-9101.

This page (NASDAQ:BLRX) was last updated on 12/5/2022 by MarketBeat.com Staff